Addition of Amgen drug boosts benefits in relapsed myeloma -study

Dec 6 (Reuters) - Significantly more patients with relapsed multiple myeloma responded to a three-drug regimen including Amgen Inc's Kyprolis than those who got the standard two-drug treatment, according to results from a late-stage trial.